<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02650167</url>
  </required_header>
  <id_info>
    <org_study_id>15-AOI-02</org_study_id>
    <nct_id>NCT02650167</nct_id>
  </id_info>
  <brief_title>Impact of Oropharyngeal Administration of Colostrum in the First 48 Hours of Life Term Premature Newborn ≤ 32 Weeks of Amenorrhea</brief_title>
  <acronym>COLOSTRUM</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colostrum is the first milk secreted by the mother when the tight junctions of mammary&#xD;
      epithelium open, allowing the cellular transport of a multitude of components and&#xD;
      immunological protective derivatives of the maternal circulation to the milk, and especially&#xD;
      immunoglobulins A type. Colostrum is not given to preterm neonates. The assumption behind&#xD;
      this work is that the oro pharyngeal administration of colostrum early in preterm infants&#xD;
      could help deliver an oral immunotherapy even before the installation of enteral nutrition,&#xD;
      through interactions with lymphoid tissues of the oropharynx and the gastrointestinal tract.&#xD;
      This practice would improve the digestive tolerance and the establishment of enteral feeding,&#xD;
      the decrease in mucosal inflammatory phenomena, but also to provide any protection against&#xD;
      subsequent infections. Finally, there could be an improvement in the secondary immune&#xD;
      tolerance with a decrease in the occurrence of allergic phenomena.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 27, 2016</start_date>
  <completion_date type="Actual">September 24, 2020</completion_date>
  <primary_completion_date type="Actual">May 5, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measuring caloric intake (number of days required for the calorie intake)</measure>
    <time_frame>2 days</time_frame>
    <description>number of days required for the calorie intake to 130 kcal / kg / day can be delivered exclusively enterally</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Infant, Premature</condition>
  <arm_group>
    <arm_group_label>Colostrum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Witness</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Colostrum feeding</intervention_name>
    <arm_group_label>Colostrum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>formula for preterm infants</intervention_name>
    <arm_group_label>Witness</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  New premature infant with a term weight ≤ 32 weeks amenorrhea at Nice University&#xD;
             Hospital&#xD;
&#xD;
          -  Mother seronegative for HIV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neonates with congenital pathologies immediate prenatal or neonatal diagnosis will not&#xD;
             be included.&#xD;
&#xD;
          -  Therapy of the mother incompatible with breastfeeding during pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphanie DE SMET, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

